LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LUCD
Lucid Diagnostics Inc.
There isn't enough reported data to score LUCD yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LUCD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
LUCD's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LUCD PE Valuation
LUCD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LUCD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LUCD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus LUCD down 177%.
LUCD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.87 | +$0.26 |
| Q2 2025 | -$1.02 | +$0.20 |
| Q1 2025 | -$1.17 | +$0.09 |
| Q4 2024 | -$1.05 | +$0.21 |
| Q3 2024 | -$1.13 | +$0.29 |
| Q2 2024 | -$1.22 | +$0.25 |
| Q1 2024 | -$1.26 | +$0.35 |
| Q4 2023 | -$1.26 | +$0.30 |
LUCD is still losing money, but less than at its worst: $0.87 per share over the past year, against $1.61 at its worst in early 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LUCD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LUCD on profitability, with a higher operating margin.
LUCD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -0.7% |
| Q2 2026 | $1.5M | +27% |
| Q1 2026 | $1.3M | +52% |
| Q4 2025 | $1.5M | +26% |
| Q3 2025 | $1.2M | +3.3% |
| Q2 2025 | $1.2M | +19% |
| Q1 2025 | $828K | -17% |
| Q4 2024 | $1.2M | +15% |
LUCD's revenue is growing: $1M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | -49 points |
| Q2 2026 | -868% | +110 points |
| Q1 2026 | -964% | +544 points |
| Q4 2025 | -932% | +102 points |
| Q3 2025 | -971% | +27 points |
| Q2 2025 | -979% | +168 points |
| Q1 2025 | -1508% | -430 points |
| Q4 2024 | -1034% | +67 points |
LUCD's operating margin was −1020% last quarter, down 49 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with LUCD at down 56%.
LUCD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.6M | -$4.7M |
| Q2 2026 | -$11.3M | -$769K |
| Q1 2026 | -$12.3M | +$149K |
| Q3 2025 | -$10.9M | -$718K |
| Q2 2025 | -$10.5M | +$933K |
| Q1 2025 | -$12.5M | +$147K |
| Q1 2024 | -$12.6M | -$5.6M |
| Q1 2023 | -$7.1M | -$1.1M |
LUCD has burned cash in almost every quarter: −$50M over the past year, against −$43M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LUCD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LUCD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.3% | +7.8M shares |
| 1 year | +93% | +92M shares |
| 3 years | +366% | +150M shares |
| 5 years | +416% | +154M shares |
| Available history | +416% | +154M shares |
LUCD has 191M diluted shares, up 93% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LUCD Net Leverage
LUCD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LUCD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 14.0 | Oversold |
LUCD's weekly RSI is 24 (oversold) and its Stochastic is 14 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LUCD PE vs Healthcare Sector
LUCD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LUCD on trend strength, trading above more of its moving averages.
LUCD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.52 | 19% below |
| 20 week MA | $0.77 | 45% below |
| 50 week MA | $1.00 | 58% below |
| 100 week MA | $1.09 | 61% below |
| 200 week MA | $1.14 | 63% below |
LUCD is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LUCD on returns for 2026, with the stronger performance.
LUCD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.35 | $4.92 | -47% |
| 2022 | $4.92 | $1.40 | -72% |
| 2023 | $1.40 | $1.41 | +0.7% |
| 2024 | $1.41 | $0.79 | -44% |
| 2025 | $0.79 | $1.09 | +38% |
| 2026 YTD | $1.09 | $0.42 | -61% |
LUCD has finished lower in three of the last five years. It's down 61% so far in 2026.